- Home
- FOF vs SLN Comparison
FOF vs SLN Comparison
Compare FOF & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- SLN
- Stock Information
- Founded
- FOF 2006
- SLN 1994
- Country
- FOF United States
- SLN United Kingdom
- Employees
- FOF N/A
- SLN N/A
- Industry
- FOF Investment Managers
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- SLN Health Care
- Exchange
- FOF Nasdaq
- SLN Nasdaq
- Market Cap
- FOF 357.8M
- SLN 345.3M
- IPO Year
- FOF N/A
- SLN N/A
- Fundamental
- Price
- FOF $12.82
- SLN $6.25
- Analyst Decision
- FOF
- SLN Buy
- Analyst Count
- FOF 0
- SLN 6
- Target Price
- FOF N/A
- SLN $39.67
- AVG Volume (30 Days)
- FOF 58.7K
- SLN 196.3K
- Earning Date
- FOF 01-01-0001
- SLN 11-06-2025
- Dividend Yield
- FOF 9.07%
- SLN N/A
- EPS Growth
- FOF N/A
- SLN N/A
- EPS
- FOF N/A
- SLN N/A
- Revenue
- FOF N/A
- SLN $25,830,000.00
- Revenue This Year
- FOF N/A
- SLN N/A
- Revenue Next Year
- FOF N/A
- SLN N/A
- P/E Ratio
- FOF N/A
- SLN N/A
- Revenue Growth
- FOF N/A
- SLN 40.39
- 52 Week Low
- FOF $9.59
- SLN $1.97
- 52 Week High
- FOF $11.75
- SLN $8.88
- Technical
- Relative Strength Index (RSI)
- FOF 48.34
- SLN 44.99
- Support Level
- FOF $12.50
- SLN $5.91
- Resistance Level
- FOF $13.14
- SLN $7.00
- Average True Range (ATR)
- FOF 0.16
- SLN 0.54
- MACD
- FOF -0.01
- SLN -0.10
- Stochastic Oscillator
- FOF 66.88
- SLN 40.00
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.